Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTQ8AFT)

• DTT Name: Adrenergic receptor Alpha-2 (ADRA2) DTT Info
• Gene Name: ADRA2

Molecule-Related Drug & Molecule List

15 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apraclonidine	DMO4PVE	Intra ocular pressure reduction	9C40	Approved	[1]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[2]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[3]
Dexmedetomidine	DM93L4X	Irritability	MB24	Approved	[4]
Guanabenz	DM5QWEL	High blood pressure	BA00	Approved	[5]
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[6]
Guanidine Hydrochloride	DM0P63W	Muscle fatigue	FB32.5	Approved	[7]
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[8]
Meperidine	DMX4GND	Pain	MG30-MG3Z	Approved	[9]
Methyldopate Hydrochloride	DM8XI09	Hypertension	BA00-BA04	Approved	[10]
Nicergoline	DMBCM8L	Brain ischaemia	8B1Z	Approved	[11]
Oxymetazoline	DM8ZXT6	Arrhythmia	BC9Z	Approved	[12]
Sodium chloride	DMM3950	Skin burns	ME65.0	Approved	[3]
Tizanidine	DMR2IQ4	Spasm	MB47.3	Approved	[13]
Yohimbine	DMJCP1Y	Erectile dysfunction	HA01.1	Approved	[14]

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fadolmidine	DM6RKG3	Neuropathic pain	8E43.0	Phase 2	[15]
Fipamezole	DMG439E	Acute myeloid leukaemia	2A60	Phase 2	[16]

3 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mivazerol	DMXT36M	Angina pectoris	BA40	Discontinued in Phase 3	[17]
Atipamezole	DM10XWU	Male sexual disorder	HA02.0	Discontinued in Phase 2	[18]
ADX415	DM61AV4	Hypertension	BA00-BA04	Terminated	[19]

2 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brominide tartrate	DMMC4BY	Discovery agent	N.A.	Investigative	[20]
[3H]rauwolscine	DMBQZ2H	Discovery agent	N.A.	Investigative	[21]

References

• [1] Apraclonidine attenuates the increases in spinal excitatory amino acid release in rats with adjuvant-induced inflammation. Anesth Analg. 2002 Mar;94(3):701-5; table of contents.
• [2] Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90.
• [3] Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
• [4] Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
• [5] Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
• [6] Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
• [7] Guanidine-based 2-adrenoceptor ligands: Towards selective antagonist activity.Eur J Med Chem.2014 Jul 23;82:242-54.
• [8] Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
• [9] Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
• [10] Effect of Antihypertensive Therapy with Alpha Methyldopa on Levels of Angiogenic Factors in Pregnancies with Hypertensive Disorders
• [11] Effect of non-selective alpha-adrenergic receptor antagonist nicergoline on the activity of neurons in the ventral lateral thalamic nucleus. Fiziol Zh. 2005;51(4):29-35.
• [12] Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
• [13] Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
• [14] Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
• [17] Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia. 1999 Feb;54(2):146-65.
• [18] Low doses of alpha 2-adrenoceptor antagonists augment spinal morphine analgesia and inhibit development of acute and chronic tolerance. Br J Pharmacol. 2008 Dec;155(8):1264-78.
• [19] Clinical pipeline report, company report or official report of Shionogi (2011).
• [20] Alpha(2A)-adrenoceptor: G(alphai1) protein-mediated pertussis toxin-resistant attenuation of G(s) coupling to the cyclic AMP pathway. Biochem Pharmacol. 2000 Jun 15;59(12):1531-8.
• [21] Characterization of alpha-adrenoceptor subtypes in smooth muscle of equine ileum. Am J Vet Res. 2001 Sep;62(9):1370-4.